These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

153 related items for PubMed ID: 15029989

  • 1. Risperidone compared with olanzapine in a naturalistic clinical study in Ireland: a cost analysis.
    Lucey JV, Libretto SE.
    Ir J Med Sci; 2003; 172(4):195-201. PubMed ID: 15029989
    [Abstract] [Full Text] [Related]

  • 2. Risperidone compared with olanzapine in a naturalistic clinical study: a cost analysis.
    Taylor DM, Wright T, Libretto SE, Risperidone Olanzapine Drug Outcomes Studies in Schizophrenia (RODOS) U.K. Investigator Group.
    J Clin Psychiatry; 2003 May; 64(5):589-97. PubMed ID: 12755664
    [Abstract] [Full Text] [Related]

  • 3. Pharmacy cost evaluation of risperidone, olanzapine, and quetiapine for the treatment of schizophrenia in acute care inpatient settings.
    Mladsi DM, Grogg AL, Irish WD, Lopez RB, Degen K, Swann A, Nimsch CT.
    Curr Med Res Opin; 2004 Dec; 20(12):1883-93. PubMed ID: 15701206
    [Abstract] [Full Text] [Related]

  • 4. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
    Llorca PM, Miadi-Fargier H, Lançon C, Jasso Mosqueda G, Casadebaig F, Philippe A, Guillon P, Mehnert A, Omnès LF, Chicoye A, Durand-Zaleski I.
    Encephale; 2005 Dec; 31(2):235-46. PubMed ID: 15959450
    [Abstract] [Full Text] [Related]

  • 5. Risperidone olanzapine drug outcomes studies in schizophrenia (RODOS): health economic results of an international naturalistic study.
    Kasper S, Jones M, Duchesne I, RODOS Investigator Group.
    Int Clin Psychopharmacol; 2001 Jul; 16(4):189-96. PubMed ID: 11459332
    [Abstract] [Full Text] [Related]

  • 6. Comments on cost analysis of risperidone versus olanzapine.
    Duggal HS, Gandotra G.
    J Clin Psychiatry; 2004 Jun; 65(6):879-80; author reply 880. PubMed ID: 15291670
    [No Abstract] [Full Text] [Related]

  • 7. Cost of antipsychotic polypharmacy in the treatment of schizophrenia.
    Zhu B, Ascher-Svanum H, Faries DE, Correll CU, Kane JM.
    BMC Psychiatry; 2008 Apr 04; 8():19. PubMed ID: 18394168
    [Abstract] [Full Text] [Related]

  • 8. Association of co-morbidities with prescribing patterns and cost savings: olanzapine versus risperidone for schizophrenia.
    Yu W, Ren XS, Lee AF, Herz L, Huang YH, Kazis LE.
    Pharmacoeconomics; 2006 Apr 04; 24(12):1233-48. PubMed ID: 17129077
    [Abstract] [Full Text] [Related]

  • 9. Olanzapine versus risperidone in the treatment of schizophrenia : a comparison of costs among Texas Medicaid recipients.
    Rascati KL, Johnsrud MT, Crismon ML, Lage MJ, Barber BL.
    Pharmacoeconomics; 2003 Apr 04; 21(10):683-97. PubMed ID: 12828491
    [Abstract] [Full Text] [Related]

  • 10. The impact of olanzapine, risperidone, or haloperidol on the cost of schizophrenia care in a medicaid population.
    Gibson PJ, Damler R, Jackson EA, Wilder T, Ramsey JL.
    Value Health; 2004 Apr 04; 7(1):22-35. PubMed ID: 14720128
    [Abstract] [Full Text] [Related]

  • 11. Cost-effectiveness of olanzapine as first-line treatment for schizophrenia: results from a randomized, open-label, 1-year trial.
    Tunis SL, Faries DE, Nyhuis AW, Kinon BJ, Ascher-Svanum H, Aquila R.
    Value Health; 2006 Apr 04; 9(2):77-89. PubMed ID: 16626411
    [Abstract] [Full Text] [Related]

  • 12. Outcomes and costs of risperidone versus olanzapine in patients with chronic schizophrenia or schizoaffective disorders: a Markov model.
    Vera-Llonch M, Delea TE, Richardson E, Rupnow M, Grogg A, Oster G.
    Value Health; 2004 Apr 04; 7(5):569-84. PubMed ID: 15367252
    [Abstract] [Full Text] [Related]

  • 13. Drug utilization patterns and outcomes associated with in-hospital treatment with risperidone or olanzapine.
    Procyshyn RM, Zerjav S.
    Clin Ther; 1998 Apr 04; 20(6):1203-17; discussion 1192-3. PubMed ID: 9916613
    [Abstract] [Full Text] [Related]

  • 14. Comments to the editor on "Outcomes and costs of risperidone versus olanzapine in patients with chronic schizophrenia or schizoaffective disorders: a Markov model".
    Clewell JD, Baker RW.
    Value Health; 2005 Apr 04; 8(2):175-6. PubMed ID: 15804326
    [No Abstract] [Full Text] [Related]

  • 15. Economic outcomes associated with olanzapine versus risperidone in the treatment of uncontrolled schizophrenia.
    Zhao Z.
    Curr Med Res Opin; 2004 Jul 04; 20(7):1039-48. PubMed ID: 15265249
    [Abstract] [Full Text] [Related]

  • 16. Comparison of discharge rates and drug costs for patients with schizophrenia treated with risperidone or olanzapine.
    Kelly DL, Nelson MW, Love RC, Yu Y, Conley RR.
    Psychiatr Serv; 2001 May 04; 52(5):676-8. PubMed ID: 11331805
    [Abstract] [Full Text] [Related]

  • 17. A population-based cost-effectiveness analysis of olanzapine and risperidone among ambulatory patients with schizophrenia.
    Cooper D, Moisan J, Abdous B, Grégoire JP.
    Can J Clin Pharmacol; 2008 May 04; 15(3):e385-97. PubMed ID: 18953083
    [Abstract] [Full Text] [Related]

  • 18. Cost evaluation of risperidone compared with olanzapine.
    Byerly MJ, Weber M, Brooks D, Casey SB, Elliot S, Hawkins J.
    Psychiatr Serv; 2003 May 04; 54(5):742-4. PubMed ID: 12719509
    [Abstract] [Full Text] [Related]

  • 19. Decision analysis model evaluating the cost-effectiveness of risperidone, olanzapine and haloperidol in the treatment of schizophrenia.
    Bounthavong M, Okamoto MP.
    J Eval Clin Pract; 2007 Jun 04; 13(3):453-60. PubMed ID: 17518814
    [Abstract] [Full Text] [Related]

  • 20. Comparing the cost effectiveness of risperidone and olanzapine in the treatment of schizophrenia using the net-benefit regression approach.
    De Ridder A, De Graeve D.
    Pharmacoeconomics; 2009 Jun 04; 27(1):69-80. PubMed ID: 19178125
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.